Literature DB >> 2558044

Retinoic acid receptor expression vector inhibits differentiation of F9 embryonal carcinoma cells.

A S Espeseth1, S P Murphy, E Linney.   

Abstract

Expression vectors have been constructed for a region of the human retinoic acid receptor-alpha (hRAR-alpha) and transferred into F9 embryonal carcinoma (EC) cells. When the vectors are overexpressed in F9 cells, clones can be selected for resistance to retinoic acid-induced differentiation. This effect is obtained even when the hRAR-alpha region is expressed as a beta-galactosidase fusion protein. Using the beta-galactosidase component of the fusion protein as a marker, overexpression of the fusion protein has been correlated with the retinoic acid-resistance effect. The clones resistant to retinoic acid no longer exhibit the normal retinoic acid induction of endo B cytokeratin, laminin B-1, and tissue plasminogen activator mRNAs observed with normal F9 cells. Retinoic acid induction of type IV alpha-1 collagen and Hox-1.3 RNAs is observed with these clones. When transfected with a thyroid receptor DNA-binding sequence (TRE)/thymidine kinase promoter/luciferase construct, the retinoic acid-resistant clones do not yield the same retinoic acid-induced level of luciferase obtained with F9 cells. It is hypothesized that the RAR vectors are interfering with endogenous RAR(s) in a dominant-negative manner to inhibit retinoic acid-induced differentiation of F9 EC cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2558044     DOI: 10.1101/gad.3.11.1647

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  17 in total

1.  Terminal differentiation in keratinocytes involves positive as well as negative regulation by retinoic acid receptors and retinoid X receptors at retinoid response elements.

Authors:  B J Aneskievich; E Fuchs
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

Review 2.  The negative side of retinoic acid receptors.

Authors:  Elwood Linney; Susan Donerly; Laura Mackey; Betsy Dobbs-McAuliffe
Journal:  Neurotoxicol Teratol       Date:  2011-07-13       Impact factor: 3.763

3.  A dominant negative mutation of the alpha retinoic acid receptor gene in a retinoic acid-nonresponsive embryonal carcinoma cell.

Authors:  M A Pratt; J Kralova; M W McBurney
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

4.  Ligand-dependent occupancy of the retinoic acid receptor beta 2 promoter in vivo.

Authors:  A Dey; S Minucci; K Ozato
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

5.  Functional inhibition of retinoic acid response by dominant negative retinoic acid receptor mutants.

Authors:  K Damm; R A Heyman; K Umesono; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

6.  Local sources of retinoic acid coincide with retinoid-mediated transgene activity during embryonic development.

Authors:  M C Colbert; E Linney; A S LaMantia
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

7.  Transcriptional control of c-jun by retinoic acid.

Authors:  R P de Groot; C Pals; W Kruijer
Journal:  Nucleic Acids Res       Date:  1991-04-11       Impact factor: 16.971

8.  Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress.

Authors:  K D Sarge; S P Murphy; R I Morimoto
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

9.  Dominant negative retinoid X receptor beta inhibits retinoic acid-responsive gene regulation in embryonal carcinoma cells.

Authors:  S Minucci; D J Zand; A Dey; M S Marks; T Nagata; J F Grippo; K Ozato
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

10.  Transgenic indicator mice for studying activated retinoic acid receptors during development.

Authors:  W Balkan; M Colbert; C Bock; E Linney
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.